Reuters Health (12.07.01) - Friday, December 21, 2001
Emma Hitt, PhD

The researchers studied two molecules, called DC-SIGN and DC- SIGNR that appear to enhance the efficiency with which HIV infects T cells. Because HIV targets the immune system's T cells, understanding the interaction at the molecular level should help in preventing HIV infection.

"The particular cells that have DC-SIGN on their surface are found in these tissues lining the cervix, uterus and rectum, which of course are where sexually transmitted HIV will be encountered," Weis told Reuters. "Likewise," Weis said, "the other molecule, DC-SIGNR, is found on the lining of capillaries in the lymph nodes and placenta" - which may account for how the virus crosses from mother to fetus.

Using x-ray crystallography to visualize the interaction between HIV and DC-SIGN and DC-SIGNR, the investigators found that the molecules both have regions that recognize specific parts of HIV - specifically a type of carbohydrate attached to the surface protein of the virus. The interactions "represent a potential target for anti-HIV therapy," Weis said. "We hope to use this information in collaboration with chemists to design therapeutic agents that would block HIV's ability to attach to these receptors."

The therapy that could be developed would be preventative and not an HIV treatment. "It may turn out to be a potentially useful target to slow infections already present," he noted, although that possibility "doesn't seem likely."
011221
AD012221

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.